BRITISH MEDICAL JOURNAL 2

L. S. PEPT, OF ANSKOUNDE MATTHAL AGRICULTAS, 1985. TEOSIVED

SEP 10 1900

HEROOF PERMENT OF COMM TURNER SCRIPT SERVICE

28 AUGUST-4 SEPTEMBER 1982

LEADING ARTICLES	
Congenital cataract: a cause of preventable blindness in children NSCRICE, DTAYLOR	Preterm rupture of the membranes JAMES OWEN DRIFE . 583 Ketoconazole RODERICK HAY
CLINICAL RESEARCH • PAPERS AND S	HORT REPORTS • PRACTICE OBSERVED
II: Selective during third trimester only OACVIEGAS, PH SCOTT, T Influence of previous gold toxicity on subsequent development of pe	H SCOTT, T J COLE, H N MANSFIELD, PAMELA WHARTON, B A WHARTON 589
	ase DAVID R M LINDSELL, ALAN G WILSON, J DOUGLAS MAXWELL 597
Relationship between cigarette yields, puffing patterns, and smoke in	ntake: evidence for tar compensation?
Mesotheliomas and asbestos type in asbestos textile workers: a stud- Segmental necrotising glomerulonephritis with antineutrophil antibo	y of lung contents JC WAGNER, G BERRY, F D POOLEY
Molluscum contagiosum: an unusual complication of tattooing 155	
Hypocalcaemia-induced epilepsy during lactation RAHARRAD, PGI	E KENNEDY 607
Double-blind controlled study of primidone in essential tremor: preli	iminary results L J FINDLEY, S CALZETTI
Research in General Practice: Sterilisation of women: prevalence	and outcome ALASTAIR F WRIGHT
Making a visit: an American GP practising in the NHS TOWN LEDEV	
Scandinavian and Dutch lessons in childhood road traffic accident process. Nephropathy Peter J Watkins. Diagnosis and treatment of venous thromboembolism by consultants Causes of death in sickle-cell disease in Jamaica Anthony n thomas Letter from Chicago: A little showmanship George Dunea. Any Questions? Materia Non Medica—Contribution from Pradip K Datta. Medicine and Books What's new in the new editions? CLIFFORD HAWKINS.	or attitudes M M ROBERTS
CORRESPONDENCE—List of Contents	SUPPLEMENT
	NHS reorganisation: Getting down to units ALAN BUSSEY 663
OBITUARY	Vocational training: three-year mandatory course 664
NEWS AND NOTES	Annual reviews or no annual reviews: the balance of power between the DHSS and health authorities DAVID E ALLEN 665 Surgeons introduce scheme to help sick doctors
Views	Confidentiality and the police: guidelines in Scotland 668
Medicolegal—Contempt of Court657Medical News—Double issue of BMJ659	Buying added years
BMA Notices	New CEC chairman

CORRESPONDENCE

Side effects of benoxaprofen	Atropine poisoning in early infancy	Electrocardiographic abnormalities and
M F Shadforth, MRCP, and others 645	due to Eumydrin drops	autonomic dysfunction in Guillain-
Benoxaprofen	Cynthia M Illingworth, FRCP, and others 650	Barré syndrome
A L Macnair, мв; G R Horton, мв; С D E	Problems with anticoagulants	A Hagman, MD, and K Malmberg, MD 653
Morris, MRCGP; J Haworth, MRCGP; T C	B R Boothman, MB	
Hindson, FRCP; N G M Legg, FRCSED; V	Do alcoholics recover?	P N Bamford, MRCOG, and others 653
Cooper, MRCGP; C W K Willard, MB 646	D H Marjot, FRCPSYCH 650	Coronary disease
Ethics and in-vitro fertilisation	Strengths and weaknesses of	H B Wright, FRCS, and A R Bailey, MRCP 653
M Potts, MB 647	British medicine	Managing cerebral malaria
Brodrick exhumed again	R Law, frcgp 651	
H H Pilling, MB	Malalignment of the shoulder	Nitrofurantoin-induced parotitis
Avoidance of tracheostomy in	after stroke	J P Griffin, MRCP, and R G Penn, MB 654
	G I Carpenter, MRCP	Laboratory dispute in Fife
sleep apnoea syndrome	Introduction of 100-unit insulin	L G Whitby, FRCPATH
N H Jenkins, MB; Kate A H Wheeler,	H D Breidahl, FRCP	Whom does BUPA care for?
MRCP; C A H Watts, FRCPSYCH; P J	Reversible hypothyroidism in	S L Kaye, MD; D L Gullick, MB 654
Thompson, FRACP, and Elzbieta H Sawicka,	adrenal insufficiency	Pathology and university cuts
MRCP 648	W J Jeffcoate, MRCP, and J R E Davis,	
First seven years of a new NHS mental	MRCP	MD
handicap service 1974-81	Guillain-Barré syndrome associated	Authors of the world unite
T L Pilkington, FRCPSYCH 649	with campylobacter infection	G T Watts, FRCS
Birth asphyxia	G K Molnar, MD, and others 652	
Janet A Eyre, MB, and others 649	Impact of maternal serum	Ramsbotham); Side effects of benoxaprofen
Genitourinary medicine	alpha-fetoprotein screening on	(Milena Lesna); Health Service strikes
M D Talbot, MRCP	antenatal diagnosis	(Rita Henryk-Gutt; S K Ghosh); Medical
Sphygmomanometers in hospital	Susan J Standing, BSC, and others 652	cover for Sikh women (F G Neild); Banning
and family practice	Left-handedness	boxing (A Rickards); Women in medicine
T J Thornton, MB; T C O'Dowd, MRCGP;	P O Behan, FRCP	(Margaret G Anderson; Mary Ducrow);
Anna E Livingstone, MB	Inaccuracy of London School of	Ethical conflicts (J Finlayson); You may
Water intoxication and oxytocin	Hygiene sphygmomanometer	die from "old age," but if you do you may
B H Valentine, FRCSED	G Nyberg, MD, and others 652	
D II Valentine, Presed	G Hyberg, MD, and builers 052	not be cremated (M K Williams) 655

We may return unduly long letters to the author for shortening so that we can offer readers as wide a selection as possible. We receive so many letters each week that we have to omit some of them. Letters should be typed with double spacing between lines and must be signed personally by all their authors, who should include their degrees. We cannot acknowledge their receipt unless a stamped addressed envelope or an international reply coupon is enclosed.

Correspondents should present their references in the Vancouver style (see examples in these columns). In particular, the names and initials of all authors must be given unless there are more than six, when only the first three should be given, followed by et al: and the first and last page numbers of articles and chapters should be included. Titles of papers are not, however, included in the correspondence section.

Side effects of benoxaprofen

SIR,—On 10 July (p 136) you published, alongside a letter from one of us (Dr M F Shadforth) pointing out the probable long-term benefits from benoxaprofen in rheumatoid arthritis, several other letters cautioning that the side effects of this drug were being overstated. These letters suggested that time was required to assess the drug and that a hasty decision from the Committee on Safety of Medicines would be ill advised. Perhaps the Committee on Safety of Medicines was subject to other pressures, but it did not heed the advice, since on 4 August it suspended benoxaprofen. It did not give the profession opportunity to comment, stating that urgent action was required. Why then did it not suspend the drug on 25 July? Perhaps all 3500 adverse effects and 61 deaths occurred that week. The side effects of benoxaprofen in this centre were insignificant when compared with the benefits it provided. We have many patients who developed photosensitivity but requested that

they continue the drug since the unwanted effect was preferable to the arthritis. We have patients now imploring us to obtain continuous supplies to keep their disease controlled. It seems we cannot do this and they will need to revert to other agents requiring full hospital surveillance. Almost certainly some of them will suffer uncomfortable, or even lifethreatening, side effects which could have been avoided had they remained on benoxaprofen.

By first announcing its decision to the popular press the Committee on Safety of Medicines ensured that patients would approach us when we had insufficient information to make considered decisions. It has effectively abolished the drug worldwide. This agent was synthesised and developed in Britain. Which country would allow it to be marketed when the parent country announces it is too dangerous to distribute? Dista Products, or their parent, Eli Lilly Industries, had no option but to withdraw the drug

throughout. Rheumatology has lost a potentially valuable agent.

Mistakes occur and can be forgiven. Repeated mistakes require correction. It appears that this is not the first time the Committee on Safety of Medicines has taken such a course, approaching the popular press before the profession, since we have learnt of many decisions of the Committee on Safety of Medicines from the papers before our official communication. One of us has still not received an official communication on the present matter. Nor is this the first agent with diseasemodifying properties in rheumatoid arthritis to be withdrawn because of the surveillance of the Committee on Safety of Medicines. Imperial Chemical Industries abandoned Clozic just before the drug was marketed. This was almost certainly because it felt the Committee on Safety of Medicines would not accept the incidence of side effects. This drug, too, promised to have disease-modifying